Determination of Human Apolipoproteins A-I, B, and E by Laser Nephelometry by Weisweiler, P. & Schwandt, P.
Weisweiler and Seh wandt: Immunonephelometric determination of apolipoproteins A-I, B and E 113
J. Clin. Chem. Clin. Biochem.
Vol. 22, 1984, pp. 113-118
Determination of Human Apolipoproteins A-I, B, and E
by Laser Nephelometry
By P. Weisweiler and P. Schwandt
with the technical assistance of Christine Friedl
H. Medizinische Klinik, Klinikum Großhadern, Universität München
(Received July 7/October 18, 1983)
Summary: A laser immunonephelometric procedure for the determination of human apolipoproteins A-I, B,
and E in serum and lipoproteins was developed. Coefficients of Variation were 2.3%—3.4% within-run,
4.7%—4.9% between-run. Serum apolipoprotein A-I values were similar in normal and hyperlipoproteinae-
mic subjects with a correlation coefficient of r = 0.585 to HDL-cholesterol levels. LDL-apolipoprotein B
values were highly (r = 0.935), VLDL-apolipoprotein B values less strongly (r = 0.472) correlated to the
corresponding cholesterol levels. Serum apolipoprotein E concentrations were distinctly elevated in Type III
and not correlated to cholesterol values.
Bestimmung der Humanapolipoproteine , B und E durch Lasernephelometrie
Zusammenfassung: Eine lasernephelometrische Methode zur Bestimmung der menschlichen Apolipoproteine
A-I, B und E in Serum und Lipoproteinen wurde entwickelt. Die Variationskoeffizienten waren 2,3% —
3,4% (Intraassay) und 4,7%—4,9% (Interassay). Die Serumapölipoprotein A-I-Konzentrationen waren bei
Gesunden und hyperlipoproteinämischen Patienten ähnlich mit einem Korrelationskoeffizienten von r =
0,585 zu den HDL-Cholesterinwerten. Die LDL-Apolipoprotein B-Konzentrationen waren hoch (r =
0.935), die VLDL-Apolipoprotein B-Konzentrationen weniger ausgeprägt (r = 0,472) mit den entspre-
chenden Cholesterinwerten korreliert. Die Serumapölipoprotein -Konzentrationen waren eindeutig bei der
Typ III-Hyperlipoproteinämie erhöht und korrelierten nicht mit den Cholesterinwerten.
Introduction
The close relationship of atherosclerotic vessel dis-
eases to disorders of serum lipoprotein levels has
stimulated research on the protein moieties of lipo-
proteins. Apolipoprotein A*I, the main constituent
of high-density lipoproteins (HDL), plays an impor-
tant role in the transport of peripheräl cholesterol to
the liver (1). Serum lipoproteins in the very low- and
low-density ränge (VLDL and LDL) which contain
apolipoprotein B and/or apolipoprotein E have at-
tracted considerable interest because of their ability
to interact with cell surface receptors, thereby deliv-
ering cholesterol to cells (2, 3). Various methods
have been utilized for the quantitative determination
of serum apolipoproteins, including radial immuno-
diffusion, electroimmunoassay, immunonephelome-
try, and radioimmunoassay (4, 5, 6).
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We have recently developed a rapid and sensitive
laser immunonephelometric assay for the determina-
tion of apolipoprotein E (7). This method was ex-
tended to apolipoproteins A-I and B with the aim of
studying normal and hyperlipoproteinaemic states.
Major emphasis was placed on the relations between
the concentrations of apolipoproteins A-I, B, and E
and of cholesterol in serum and lipoproteins.
Materials and Methods
General procedures
Serum samples from normal male volunteers and hyperlipoprotei-
naemic patients (aged from 23 to 65 years), taking no medication
and having fasted overnight, were analysed. The samples were
stored at 4 °C until analysis, which was performed within 2 days.
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VLDL were isolatcd from serum by ultracentrifugation at 1.006
kg/l at 40%000 min"1 for 22 hours at 4 °C in Beckman 40.3 rotors,
and the lipoprotein fractions wcre recovered by tube slicing (8). In
the 1.006 kg/l infranate HOL were separated from LDL by pre-
cipitation of LDL using a commercially available combination of
sodium phosphotungstate and magnesium Chloride according to
the described method (Boehringer-kit, Mannheim, FRG). A lipo-
protein-frec serum was obtained after ultracentrifugal flotation of
lipoproteins at 1,21 kg/l. The mass of cholesterol and triglycerides
in whole serum and separated lipoproteins was determined in an
automated analyser by enzymatic techniques (Boehringer-kits,
Mannheim, FRG). LDL-cholesterol was calculated äs the differ-
ence in the mass of cholesterol in the 1.006 kg/l infranate and in
HOL. Before assay of apolipoproteins, serum and ultracentrif-
uged fractions were stored at -30°C for up to l month. Hyperli-
poproteinaemic subjects were obtained from a group of individu-
als originally referred to the outpatient clinic. The distribution of
lipid levels was determined in the families of the propositi in order
to obtain a genetic diagnosis (9). Propositi with either (heterozy-
gous) familial hypercholesterolaemia (Type Ha) or familial com-
bined hyperlipidaemia (Type Ilb) or familial hypertriglyceridae-
mia (Type IV) were then selected for evaluation of their lipopro-
teins. Diagnosis of Type III hyperlipoproteinaemia was confirmed
by analytical isoelectric focusing of the apolipoprotein E isoforms
(10). Statistical methods included the unpaired Wilcoxon two-
sample lest and simple regression analysis using Pearson correla-
tion coefficient r (ll).'·
Preparat ion of the ant igens
Apolipoproteins A-I and E and LDL (1.030 kg/l < d < 1.050
kg/l) were used äs antigens. Apolipoproteins were isolated from
ultracentrifuged HDL (apolipoprotein A-l) and VLDL (apolipo-
protein E) by Sephacryl S 200 gel filtration äs described (12).
Apolipoprotein E was further purified by chromatofocusing (13).
LDL were prepared by 2 sequent ultracentrifugations. The ho-
mogeneity of apolipoproteins was assayed by polyacrylamide gel
electrophoresis in urea and sodium dodecyl sulphate (SDS) with
molecular weight determination (14, 15), and amino acid analysis
was performed on an automated analyser (Liquimat III, Kontron,
Munich, FRG). LDL yielded a single band on 3.5% polyacrylam-
ide gel electrophoresis in SDS with the mobility of apolipoprote-
in B-100 (16). The mass of protein in isolated apolipoproteins and
LDL was determined according to Lowry et al. (17) using human
albumin äs Standard.
P repa ra t i on of the an t i se ra
Antisera to apolipoproteins A-I and E and LDL were produced
by injecting rabbits subcutaneously on 3 occasions 14 days apart
and bleeding them 7 days after the last injection. The total amount
of antigen given per inoculation was 0.3 mg protein (apolipopro-
teins A-I and E dissolved in 0.05 ml 0.01 mol/1 NH4HCO3 buffer,
pH 8.6) and emulsified in an equal volume of complete Freund'*
adjuvant (Difco, Detroit, USA). The purity and specifity of the
antisera were checked by double immunodiffusion and immuno-
electrophoresis using whole serum and purified apolipoprotein
fractions.
L igh t - s ca t t e r i ng measu remen t s
Light-scattering was measured with a commercially available laser
nephelometer (Behringwerke, Marburg, FRG). The amount of
light-scattering was estimated from the potential difference, ex-
pressed in volts, on the digital indicator of the Instrument. Antise-
ra were diluted in 0.01 mol/1 sodium phosphate buffer, pH 7.4.
10-fold dilutions for apolipoproteins A-I and E, and a 40-fold di-
lution for apolipoprotein B of filtered (Minisart® P, Sartoriiis,
Gottingen, FRG, pore size 0.45 ) antisera were found to be
optimal for routine analysis. Sample dilutions were made with
Phosphate buffer containing 0.33 g/l hydroxypolyethoxydodecane
(Thesit®, Desitinwerke Karl Klinke, Hamburg, FRG, (18)) to fe-
move the turbidity increase artificiälly induced by triglycerides.
Dilutions were 600-fold (apolipoprotein A-I) and 100-fold (apo-
lipoproteins B and E), respectively. The nephelometry was car-
ried out either unenhanced (apolipoproteins A-I and B) or en-
hanced with 40 g/l polyethylene glycol 6000 (Serva, Heidelberg,
FRG, apolipoprotein E). The reaction mixture contained 0.2 ml
of diluted antiserum and 0.1 ml of the dilute<S sample, and was
allowed to stand for 2 hours. Apolipoprotein concentrations of
serum and of the l .006 kg/I infranate (only apolipoprotein B as-
say) were obtained from a frozen serum pool which was calibrated
by laser nephelometry against serial dilutions of isolated apolipo-
proteins and LDL in the Thesit®-phosphate buffer. A lipoprotein-
free serum was added to the LDL-standard (19). VLDL-apolipo-
protein B was calculated äs the difference between the mass of
apolipoprotein B in serum and in the infranate.
Apol ipoprote in q u a n t i t a t i o n by e lect roimmunoassay
Rocket immunoelectrophoresis was done in 12.5 g/l agarose
plates using a 0.02 mol/i barbital buffer, pH 8.6, after adding an-
tisera (0.015, 0.007, and 0.03 l/l of apolipoprotein A-I, B, and E
antisera, respectively) at 52 °C (20). 5 mm diameter holes for 15
samples were punched at the cathodal end. Serum samples were
diluted 100-fold (apolipoprotein A-I) and 20-fold (apolipoprote-
ins B and E) in barbital buffer (with additional 8 mol/1 urea for
apolipoprotein A-I (21), and 0.33 g/l Thesit® for apolipoproteins B
and E). Apolipoprotein concentrations were obtained from Stan-
dard curves of isolated apolipoproteins and LDL. For staining,
Coomassie Blue R 250 (Serva, Heidelberg, FRG) was used. The
height of the rockets was measured with a fuler to the nearest 0.5
mm. The coefficients of Variation (CV) of these assays ranged
from 2% to 5%.
Results
Analyt ica l var iables
After dilution in the Thesit®-phosphäte buffer, iso-
lated apolipoproteins A-I and E and LDL reacted
well with their specific antisera showing a linear rela-
tionship between light-scattering and protein con-
centration. An additional step to expose antigenic
sites in serum and infranate samples was not neces-
sary. The within and between assay precision was de-
termined using the calibrated serum Standard. With-
in-run Variation was assayed 20 times in one assay.
The mean concentrations were 1.31 ± 0.03 g/l, with
CV = 2.4%, for apolipoprotein A-I, 0.89 ± 0.03 g/l,
with CV = 3.4%, for apolipoprotein B, and 0.098 ±
0.002 g/l, with CV = 2.3%, for apolipoprotein E.
Run-to-run Variation was assayed 15 times during 3
weeks. The mean concentrations were 1.31 ± 0.06
g/l, with CV = 4.9, for apolipoprotein A-I; 0.89 ±
0.04 g/l, with CV = 4.7%, for apolipoprotein B; and
0.098 ± 0.004 g/l, with CV = 4.7%, for apolipopro-
tein E. We determined the limit of detection of apo-
lipoproteins by assaying dilutions of calibration Stan-
dards. Under Standard operating conditions the low^
est limits of detection were 0.10 g/l for apolipoprote-
in A-I, 0.05 g/1 for apolipoproteinü, and 0.005 g/J
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for apolipoprotein E. The comparison of results ob-
tained by laser immunonephelometry and electro-
immunoassay (12 normal and 12 hyperlipoprotein-
aemic serum samples) resulted in good correlations
between the 2 assays with slopes of the regression
line close by 1.00 (r = 0.986 for apolipoprotein A-I,
r = 0.967 for apolipoprotein B, and r = 0.939 for
apolipoprotein E).
Apol ipoprote in concen t ra t ions in se rum
and l ipopro te ins
Serum and lipoprotein concentrations and mass rati-
os of cholesterol and apolipoproteins are given in ta-
bles 1 and 2. Mean serum apolipoprotein A-I levels
in normal and hyperlipoproteinaemic subjects were
similar to each other. Mean ratios of HDL-choles-
terol to apolipoprotein A-I were significantly lower
in Type III and Type IV patients than in normal sub-
jects. The correlation coefficients between all HDL-
cholesterol and apolipoprotein A-I values and all
VLDL-cholesterol and apolipoprotein A-I values
were r = 0.585 and r = -0.266, respectively (corre-
lations except Type III patients, fig. la and Ib).
Mean serum apolipoprotein B levels were highest in
Types Ila and Ilb, indicating increased LDL-apo-
lipoprotein B concentrations. The less marked in-
crease of serum apolipoprotein B levels in Types III
and IV implied elevated concentrations of VLDL-
apolipoprotein B. LDL-apolipoprotein B represent-
ed 89.3, 92.0 and 87.4% of the serum apolipoprote-
in B in normal, Type Ila, and Type Ilb subjects, and
Tab. 2. Mass ratios of lipoprotein cholesterol to apolipoproteins
±SD, +p <0.01.
Subjects Ratio Ratio Ratio
HDL-choles- LDL-choles- VLDL-choles-
terol to teroltoLDL- teroltoVLDL-
apolipo- apolipo- apolipo-
protein A-I protein B protein B
Normal 0.38 ±0.09 1 .59 ± 0.3 1 1 .45 ± 0.99
(n = 20)
Type Ila 0.35 ± 0.08 1 .79 ± 0.29 1 .27 ± 1 .0 1
(n = 10)
Type Ilb 0.28 ± 0.06 1.74 ± 0.30 2.13 ± 1.60
(n = 10)
Type III 0.27 ± 0.03+ 1.60 ±0.21 8.0 1 ±2.41 +
(n = 3)
Type IV 0.22 ± 0.05+ 1.55 ± 0.27 2.28 ± 1.43
(n = 12)
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Figs. l a—d: Significant relationships between the concentrations of apolipoproteins and cholesterol in serum and lipoproteins
(n = 52, +p <0.05, ++p <0.001):
Slope y-intercept
Fig. la
Fig. Ib
Fig. Ic
Fig. Id
0.338
-0.089
0.379
0.324
1.213
,1.374
0.369
0.065
0.585++
-0.273+
0.935++
0.472++
77.9 and 74.8% of the total apolipoprotein B in
Type III and Type IV subjects. The mean ratios of
LDL-cholesterol to LDL-apolipoprotein B were
quite similar among groups. LDL-cholesterol was,
furthermore, strongly positively correlated with
LDL-apolipoprotein B (r = 0.935, flg. Ic). The
mean ratio of VLDL-cholesterol to VLDL-apolipo-
protein B was highest in Type III, but not significant-
ly different from normal in Types Ha, Ilb, and IV.
The correlation coefficient between all VLDL-cho-
lesterol and VLDL-apolipoprotein B values was r =
0.472 (fig. Id).
Mean serum apolipoprotein E levels in Type Ha,
Type, Ilb, and Type IV patients were similar to that
in normal subjects. Apolipoprotein E Values of pa-
tients with Type III hyperlipoproteinaemia were
nearly 4-fold higher than the other ones. Apolipo-
protein E showed no correlations with either serum
lipids or lipoprotein cholesterol.
Discussion
One ahn of these studies was to ascertain the advan-
tages of laser nephelometry. Its rapidity, simplicity,
and high precision fulfil the criteria required for
standärd-procedüres in clinical chemistry. The prob-
lem of the accuracy of apolipoprotein A-I and B im-
munoassays have been recently discussed (5, 6). För
the measurernent of these apolipoproteins äs well äs
of apolipoprotein E (22) the use of a secondary se-
rum Standard has been proposed, because the immu-
noreactivity of highly purified apolipoprotein might
be less stable than that of apolipoproteiii iri unpro-
cessed serum (23). The presence of detergent in the
concentration employed in this assay leads to a disin-
tegration of triglyceride-rich particles (24) which is
necessary to avoid nonspecific light-scattering.
Preiqcubation of hypertnglyceridaemic serum sam-
ples with lipases can tfien be omitted. The good
agreement between immunonephelometric assäy
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and electroimmunoassay provides evidence that las-
er immunonephelometry correctly estimates apo-
lipoprotein values.
Another aim of the study was to obtain serum and
lipoprotein apolipoprotein concentrations in normal
and hyperlipoproteinaemic states and to evaluate the
relations between cholesterol and apolipoproteins.
Though quite different methods have been used in
the determination of serum apolipoproteins A-I and
B, there is a reasonable agreement between the nor-
mal values in different studies (reviews, I.e. (5), (6)).
With respect to apolipoprotein E, discrepancies of
normal values (7) may be related to differences in
the apolipoprotein E preparation which is less stan-
dardized than the preparation of pure apolipoprote-
in A-I and LDL-standards.
In hyperlipoproteinaemia, apolipoprotein A-I con-
centrations have been reported to be similar to nor-
mal values (25, 26, 27). Changes in the relative pro-
portions of HDL-components may be due either to
different amounts of HDL2 (28) or to alterations in
the composition of HDL-particles (26). However, in
hypertriglyceridaemic serum samples a significant
part of apolipoprotein A-I is contributed by VLDL,
which can be avoided by precipitation of apolipopro-
tein B-containing lipoproteins prior to immunoassay
(29). In accordance with our data a weak negative
relationship between VLDL-triglycerides and apo-
lipoprotein A-I has been reported earlier (26).
With respect to apolipoprotein B we could confirm
quite similar ratios of LDL-cholesterol to LDL-apo-
lipoprotein B for normal and hyperlipoproteinaemic
subjects and an excellent relationship between both
Parameters (30—33, 35). In spite of ratios of VLDL-
cholesterol to VLDL-apolipoprotein B with consid-
erable overlap among gröups (except Type III) we
found a less strong relationship between these two
Parameters (r = 0.472) than Wieland et al. (r =
0.987 (32)). Other authors found correlation coeffi-
cients from 0.198 to 0.690 (33, 34, 35). The reason
for these discrepancies may lie in the heterogeneity
of the VLDL-composition in different types of hy-
perlipoproteinaemia, äs described for familial com-
bined hyperlipoproteinaemia ("Type Hb") and fa-
milial hypertriglyceridaemia ("Type IV") by Brun-
zell et al. (36).
Distinctly elevated apolipoprotein E concentrations
in type III hyperlipoproteinaemia have been demon-
strated in all reports (22,37-40). An incomplete ca-
tabolism of triglyceride-rich lipoproteins or unusual
synthetic products may account for a slight increase
of serum apolipoprotein E levels in other forms of
hyperlipoproteinaemia (22, 37, 39). Because of the
fact that the ultracentrifugation procedure results in
the appearance of considerable amounts of apolipo-
protein E in the lipoprotein-free fraction of serum
(22, 39), a discrimination into VLDL- and HDL-as-
sociated apolipoprotein E is problematic. In agree-
ment with Carlson & Holmquist (40) no significant
relationships could be observed between serum or
lipoprotein lipids and apolipoprotein E.
In order to appreciate the predictive ability of serum
apolipoproteins in the evaluation of the risk of ather-
osclerotic vessel diseases, laser immunonephelome-
try of apolipoproteins allows simple, fast, reliable,
and precise investigations. Further studies are neces-
sary to achieve a general standardization of apolipo-
protein immunoassays and to establish the advan-
tage of combined measurement of lipids and apo-
lipoproteins.
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